Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Nuclear Medicine
Erschienen in: Annals of Nuclear Medicine 3/2018

01.04.2018 | Review Article

Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine

verfasst von: Geetanjali Arora, Gurupad Bandopadhyaya

Erschienen in: Annals of Nuclear Medicine | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

We present a comprehensive review of Neuroendocrine Tumors (NET) and the current and developing imaging and therapeutic modalities for NET with emphasis on Nuclear Medicine modalities. Subsequently, nanotechnology and its emerging role in cancer management, especially NET, are discussed. The article is both educative and informative. The objective is to provide an insight into the developments made in nuclear medicine and nanotechnology towards management of NET, individually as well as combined together.
Literatur
1.
Oberg KE. Management of neuroendocrine tumors: current and future therapies. Exp Rev Endocrinol Metab. 2011;6:49–62.CrossRef
2.
Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANET consensus guideline for the diagnosis and management of neuroendocrine tumors (well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum). Pancreas. 2010;39:753–66.CrossRefPubMed
3.
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.CrossRefPubMed
4.
Patel YC. Somatostatin and its receptor family. Front Neuroendocrin. 1999;20:157–98.CrossRef
5.
Bal CS, Gupta SK, Zaknun JJ. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors. Trop Gastroenterol. 2010;31:87–95.PubMed
6.
Bronstein-Sitton N. Somatostatin and the somatostatin receptors: versatile regulators of biological activity. Pathways No. 2 Spring. 2006:25–7.
7.
Ardill JES, O‘Dorisio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin N Am. 2010;39:777–90.CrossRef
8.
Rufini V, Calcagni M, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–47.CrossRefPubMed
9.
10.
Teunissen JJM, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumors. Endocr Relat Cancer. 2011;18:S27–S51.CrossRefPubMed
11.
Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med. 2001;31:296–311.CrossRefPubMed
12.
Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Donohoe KJ, Krenning EP, et al. Society of nuclear medicine procedure guideline for somatostatin receptor scintigraphy with In-111 pentetreotide (version 1.0, approved February 21, 2001). Society of nuclear medicine procedure guidelines manual; 2002. p. 147–51.
13.
Dimitroulopoulos D, Zisimopoulos A, Xinopoulos D, Tsamakidis K, Andriotis E, Fotopoulou E, et al. Somatostatin receptor scintigraphy with In-111 Octreotide in the detection of gastroenteropancreatic carcinoids and their metastases. Ann Gastroenterol. 2003;16:339–45.
14.
Schillaci O. Functional–anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharm. 2004;19:129–34.CrossRefPubMed
15.
Decristoforo C, Maina T, Nock B, Gabriel M, Cordopatis P, Moncayo R. 99mTc-Demotate 1: first data in tumor patients-results of a pilot/ phase 1 study. Eur J Nucl Med Mol Imaging. 2003;30:1211–9.CrossRefPubMed
16.
Kopecky M, Trejtnar F, Laznicek M, Laznickova A, Semecky V, Maina T, et al. 99mTc Demotate 1: biodistribution and elimination characteristics in rats. Nucl Med Commun. 2005;26:549–54.CrossRefPubMed
17.
Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, et al. 99mTc Demotate 2 in the detection of SST2-positive tumors: a preclinical comparison with 111In DOTA-TATE. Eur J Nucl Med Mol Imaging. 2006;33:831–40.CrossRefPubMed
18.
Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, et al. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NET. J Nucl Med. 2008;49:1060–5.CrossRefPubMed
19.
Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751–7.CrossRefPubMed
20.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.CrossRefPubMed
21.
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864–70.CrossRefPubMed
22.
Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, et al. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res. 2007;27:4087–94.PubMed
23.
Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJG, et al. A novel facile method of labeling octreotide with 18F-fluorine. J Nucl Med. 2010;51:454–61.CrossRefPubMedPubMedCentral
24.
Laverman P, D’Souza CA, Eek A, McBride WJ, Sharkey RM, Oyen WJG, et al. Optimized labeling of NOTA-conjugated octreotide with F-18. Tumor Biol. 2012;33:427–34.CrossRef
25.
Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51:704–12.CrossRefPubMed
26.
Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY, et al. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573–86.CrossRefPubMed
27.
Minn H, Kauhanen S, Seppanen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50:1915–8.CrossRefPubMed
28.
Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer. 2003;10:497–501.CrossRefPubMed
29.
Gedik GK, Hoefnagel CA, Bais E, Olmos RAV. 131I-MIBG therapy in metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725–33.CrossRefPubMed
30.
Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003;15:193–8.CrossRef
31.
Navalkissoor S, Alhashimi DM, Quigley AM, Caplin ME, Buscombe JR. Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:904–12.CrossRefPubMed
32.
Riad R, Kotb M, Omar W, Zaher A, Ebied E, Pitman AG, et al. I-131 mibg therapy for advanced stage III and IV neuroblastoma. J Cancer Ther. 2011;2:481–9.CrossRef
33.
Grunwald F, Ezziddin S. 131I-Metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2010;40:153–63.CrossRefPubMed
34.
35.
Brechbiel MW. Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging. 2008;52:166–73.PubMed
36.
de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WAP, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133–40.CrossRefPubMed
37.
Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJM, van Eijck CHJ, Valkema R, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53–R73.CrossRefPubMed
38.
Ozkan E, Tokmak E, Kucuk NO. Efficacy of adding high-dose In-111 octreotide therapy during sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients. Ann Nucl Med. 2011;25:425–31.CrossRefPubMed
39.
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439–47.CrossRefPubMed
40.
Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-Dota]-D-Phe1Tyr3Octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:41–945.CrossRef
41.
Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and Tandem 90Y/177Lu- DOTATATE: which is a better therapy option. Eur J Nucl Med Mol Imaging. 2011;38:1788–97.CrossRefPubMedPubMedCentral
42.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62.CrossRefPubMed
43.
Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate. J Clin Oncol. 2004;22:2724–9.CrossRefPubMed
44.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] Octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.CrossRefPubMed
45.
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.CrossRefPubMed
46.
Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [177Lu-DOTA0,Tyr3] Octreotate and [177Lu- DOTA0, Tyr3] Octreotide: which peptide is preferable for PRRT. Eur J Nucl Med Mol Imaging. 2006;33:1346–51.CrossRefPubMed
47.
Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTA-TATE and 177Lu-DOTA-NOC. Cancer Biother Radiopharm. 2007;22:406–16.CrossRefPubMed
48.
de Jong M, Breeman WAP, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46:13S–17S.PubMed
49.
Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, et al. Treatment with Tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54:84–91.PubMed
50.
Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging. 2010;54:92–9.PubMed
51.
Pach D, Sowa-Staszczak A, Kunikowska J, Królicki L, Trofimiuk M, Stefanska A, et al. Repeated cycles of peptide receptor radionuclide therapy (PRRT)—results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE Or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiother Oncol. 2012;102:45–50.CrossRefPubMed
52.
Cremonesi M, Botta F, Dia AD, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. a review. Q J Nucl Med Mol Imaging. 2010;54:37–51.PubMed
53.
Vegt E, de Jong M, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58.CrossRefPubMed
54.
Wang X, Yang L, Chen Z, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58:97–110.CrossRefPubMed
55.
56.
Kairemo K, Erba P, Bergstrom K, Pauwels EKJ. Nanoparticles in cancer. Curr Radiopharm. 2008;1:30–6.CrossRef
57.
Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide–liposome conjugates in internal radiotherapy. J Nucl Med. 2001;42:499–504.PubMed
58.
Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters A, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7:243–54.PubMed
59.
Wang SX, Bao A, Herrera SJ, Phillips WT, Goins B, Santoyo C, et al. Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res. 2008;14:3975–83.CrossRefPubMed
60.
Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2:8–21.CrossRefPubMed
61.
Lee SC, Oh JT, Jang MH, Chung S. Quantitative analysis of polyvinyl alcohol on the surface of poly-(d,l-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. J Control Release. 1999;59:123–32.CrossRefPubMed
62.
Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology. 2010;151:458–65.CrossRefPubMed
63.
Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2:469–78.CrossRefPubMed
64.
Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318.PubMed
65.
Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93–102.CrossRefPubMed
66.
Fazel-Rezai R. Biomedical engineering—from theory to applications. Ebook published by InTech 2011, ISBN 978-953-307-637-9, Chapter 13.
67.
Harrington KJ, Lewanski CR, Stewart JS. Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development. Clin Oncol (R Coll Radiol). 2000;12:2–15.
68.
Harrington KJ, Lewanski CR, Stewart JS. Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clin Oncol (R Coll Radiol). 2000;12:16–24.
69.
Rossin R, Pan D, Qi K, Turner JL, Sun X, Wooley KL, et al. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med. 2005;46:1210–8.PubMed
70.
Shukla J, Bandopadhyaya GP, Varma IK. 188Rhenium(V)-Dimercaptosuccinic acid loaded Poly-(Lactic-Co-Glycolic) acid microspheres for targeted radiotherapy: production and effectivity. Pharmazie. 2005;60:583–7.PubMed
71.
DeNardo SJ, DeNardo GL, Natarajan A, Miers LA, Foreman AR, Gruettner C, et al. Thermal Dosimetry Predictive Of Efficacy of 111In-ChL6 nanoparticle AMF–induced thermoablative therapy for human breast cancer in mice. J Nucl Med. 2007;48:437–44.CrossRefPubMed
72.
McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med. 2007;48:1180–9.CrossRefPubMed
73.
Helbok A, Decristoforo C, Dobrozemsky G, Rangger C, Diederen E, Stark B, et al. Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals. J Liposome Res 2010;20:219–27.CrossRefPubMed
74.
75.
Ocampo-García BE, Ramírez Fde M, Ferro-Flores G, De León-Rodríguez LM, Santos-Cuevas CL, Morales-Avila E, et al. (99 m)Tc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. Nucl Med Biol. 2011;38:1–11.CrossRefPubMed
76.
Tang QS, Chen DZ, Xue WQ, Xiang JY, Gong YC, Zhang L, et al. Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-Folate-CDDP/HSA Mnps) in vivo. Int J Nanomed. 2011;6:3077–85.
77.
78.
79.
80.
Surujpaul PP, Gutiérrez-Wing C, Ocampo-García B, Ramírez F, de Murphy CA, Pedraza-López M, et al. Gold nanoparticles conjugated to [Tyr3]Octreotide peptide. Biophys Chem. 2008;138:83–90.CrossRefPubMed
81.
Dubey N, Varshney R, Shukla J, Ganeshpurkar A, Hazari PP, Bandopadhaya GP, et al. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Deliv. 2012;19:132–42.CrossRefPubMed
82.
Dubey N, Shukla J, Hazari PP, Varshney R, Ganeshpurkar A, Mishra AK, et al. Preparation and biological evaluation of paclitaxel loaded biodegradable PCL/PEG nanoparticles for the treatment of human neuroendocrine pancreatic tumor in mice. Hell J Nucl Med. 2012;15:9–15.PubMed
83.
84.
Arora G, Dubey P, Shukla J, Ghosh S, Bandopadhyaya G. Evaluation of cytotoxic and tumor targeting capability of (177)Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy. Ann Nucl Med. 2016;30:334–45.CrossRefPubMed
Metadaten
Titel
Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine
verfasst von
Geetanjali Arora
Gurupad Bandopadhyaya
Publikationsdatum
01.04.2018
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 3/2018
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1235-2

Weitere Artikel der Ausgabe 3/2018

Annals of Nuclear Medicine 3/2018 Zur Ausgabe

Original Article

18F-FPYBF-2, a new F-18-labelled amyloid imaging PET tracer: first experience in 61 volunteers and 55 patients with dementia

Original Article

Relationship between collateral circulation and myocardial viability of 18F-FDG PET/CT subtended by chronic total occluded coronary arteries

Original Article

Automated segmentation and detection of increased uptake regions in bone scintigraphy using SPECT/CT images

Original Article

The influence of elevated hormone levels on physiologic accumulation of 68Ga-DOTATOC

Report

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Original Article

Is 123I-metaiodobenzylguanidine heart-to-mediastinum ratio dependent on age? From Japanese Society of Nuclear Medicine normal database